• OPEN AN ACCOUNT
Indian Indices
Nifty
25,461.00 55.70
(0.22%)
Sensex
83,432.89 193.42
( 0.23%)
Bank Nifty
57,031.90 239.95
( 0.42%)
Nifty IT
39,166.55 312.25
( 0.80%)
Global Indices
Nasdaq
44,849.54 344.11
(0.77%)
Dow Jones
6,300.35 51.93
(0.83%)
Hang Seng
39,792.23 6.33
(0.02%)
Nikkei 225
8,822.91 -0.29
(0.00%)
Forex
USD-INR
85.44 -0.20
(-0.23%)
EUR-INR
100.61 -0.32
(-0.32%)
GBP-INR
116.59 -0.52
(-0.45%)
JPY-INR
0.59 0.00
(-0.64%)

EQUITY - MARKET SCREENER

Wanbury Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524212
INE107F01022
18.0865417
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
WANBURY
29.55
902.66
EPS(TTM)
Face Value()
Div & Yield %
9.32
10
0
 

SPARC tanks after psoriasis, eczema drug flunks Phase 2 trials
Jun 04,2025
In a regulatory filing, SPARC said that its partner, Sun Pharmaceutical Industries (SPIL), reported top-line results from Phase 2 studies of Vibozilimod (SCD-044), a drug candidate aimed at treating moderate-to-severe psoriasis and atopic dermatitis.

Both trials failed to meet their primary endpoints: a 75% improvement in the Psoriasis Area and Severity Index (PASI75) and Eczema Area and Severity Index (EASI75), respectively, by Week 16.

Following the setback, SPARC and SPIL stated they would assess the appropriate next steps for the development of Vibozilimod.

SPARC is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.

On a consolidated basis, SPARC reported net loss of Rs 59.77 crore in Q4 March 2025 as against net loss of Rs 105.79 crore in Q4 March 2024. Net sales rose 64.19% year-on-year to Rs 27.19 crore in Q4 March 2025.